Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
STMC-103H is a novel Next-Generation Probiotics (NGPs) developed by Siolta Therapeutics Inc., designed to prevent and treat atopic (allergic) diseases in newborns and infants who are at increased risk due to family history. STMC-103H is a defined consortium of three beneficial bacterial species, specifically selected because they are commonly depleted in the gut microbiota of infants who later develop allergic sensitization and atopic diseases.
Source: Company information
see also:
NCT05003804 - ADORED - STMC-103H & Atopic Dermatitis / Atopic Eczema (prevention)
…